Kodiak Sciences Inc
NASDAQ:KOD

Watchlist Manager
Kodiak Sciences Inc Logo
Kodiak Sciences Inc
NASDAQ:KOD
Watchlist
Price: 25 USD -3.92%
Market Cap: 1.3B USD

Kodiak Sciences Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Kodiak Sciences Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Kodiak Sciences Inc
NASDAQ:KOD
Net Income (Common)
-$217.3m
CAGR 3-Years
15%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Kodiak Sciences Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 93 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.

KOD Intrinsic Value
Not Available

See Also

What is Kodiak Sciences Inc's Net Income (Common)?
Net Income (Common)
-217.3m USD

Based on the financial report for Sep 30, 2025, Kodiak Sciences Inc's Net Income (Common) amounts to -217.3m USD.

What is Kodiak Sciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-16%

Over the last year, the Net Income (Common) growth was -13%. The average annual Net Income (Common) growth rates for Kodiak Sciences Inc have been 15% over the past three years , -16% over the past five years .

Back to Top